3 selected items - GEO DataSets

Warning: The NCBI web site requires JavaScript to function. more...

Format

Summary
Summary (text)
Unique Identifier List

Sort by

Default order
Number of Samples (High to Low)
Number of Samples (Low to High)

Send to:

Choose Destination

File
Clipboard
Collections

Selected items

Items: 3

Select item 58201.

αSMA+ myofibroblast early depletion effect on pancreatic ductal adenocarcinoma model

Analysis of pancreatic ductal adenocarcinoma (PDAC) tumors from PKT; αSMA-tk+ transgenics injected daily with ganciclovir at 4 to 4.5 weeks of age for 14 days or less to selectively deplete αSMA+ myofibroblasts. Results provide insight into the role of αSMA+ myofibroblasts in early-stage PDAC.

Organism:: Mus musculus

Type:: Expression profiling by array, count, 2 protocol sets

Platform:: GPL6887
Series:: GSE52812
6 Samples

Download data

DataSet

Accession:: GDS5820

ID:: 5820

PubMed Full text in PMC Similar studies GEO Profiles Analyze DataSet

Select item 58212.

αSMA+ myofibroblast late depletion effect on pancreatic ductal adenocarcinoma model

Analysis of pancreatic ductal adenocarcinoma (PDAC) tumors from PKT; αSMA-tk+ transgenics injected daily with ganciclovir at 6 weeks of age for 10 days or less to selectively deplete αSMA+ myofibroblasts. Results provide insight into the role of αSMA+ myofibroblasts in late-stage PDAC.

Organism:: Mus musculus

Type:: Expression profiling by array, count, 2 protocol sets

Platform:: GPL6887
Series:: GSE52812
6 Samples

Download data

DataSet

Accession:: GDS5821

ID:: 5821

PubMed Full text in PMC Similar studies GEO Profiles Analyze DataSet

Select item 58223.

Anti-CTLA-4 immunotherapy effect on αSMA+ myofibroblast late-depleted pancreatic ductal adenocarcinoma model

Analysis of pancreatic ductal adenocarcinoma (PDAC) tumors from PKT; αSMA-tk+ transgenics injected daily with ganciclovir at 6 weeks of age for 10 days or less to deplete αSMA+ myofibroblasts and treated with anti-CTLA4. Results provide insight into molecular basis of anti-CTLA4 therapy in PDAC.